[{"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1371, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 65, "title": "Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1627576, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Horn", "age": 46, "title": "Executive VP of Corporate Strategy & CFO", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 947770, "exercisedValue": 0, "unexercisedValue": 261805}, {"maxAge": 1, "name": "Mr. John Richard Pinion II", "age": 59, "title": "Chief Quality Operations Officer & Executive VP of Translational Sciences", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 923934, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Erik  Harris M.B.A.", "age": 55, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 985266, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Crombez M.D.", "age": 52, "title": "Chief Medical Officer & Executive VP", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 987676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 54, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karah Herdman Parschauer J.D.", "age": 47, "title": "Chief Legal Officer & Executive VP of Corporate Affairs", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 846744, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ernie W. Meyer", "age": 60, "title": "Chief Human Resources Officer & Executive VP", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vimal  Srivastava", "age": 60, "title": "Senior Vice President of Business Development & Alliance Management", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dennis Karl Huang", "age": 60, "title": "Chief Technical Operations Officer and Executive VP of Gene Therapy Operations", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 331330, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 2, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 21.83, "open": 21.56, "dayLow": 21.31, "dayHigh": 22.87, "regularMarketPreviousClose": 21.83, "regularMarketOpen": 21.56, "regularMarketDayLow": 21.31, "regularMarketDayHigh": 22.87, "payoutRatio": 0.0, "beta": 0.155, "forwardPE": -908.8, "volume": 2088758, "regularMarketVolume": 2088758, "averageVolume": 2641038, "averageVolume10days": 2572020, "averageDailyVolume10Day": 2572020, "bid": 22.34, "ask": 23.14, "bidSize": 20, "askSize": 20, "marketCap": 2191970304, "fiftyTwoWeekLow": 18.41, "fiftyTwoWeekHigh": 45.0, "allTimeHigh": 179.647, "allTimeLow": 18.41, "priceToSalesTrailing12Months": 3.2570138, "fiftyDayAverage": 27.499, "twoHundredDayAverage": 31.3388, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2769884672, "profitMargins": -0.85438, "floatShares": 93022924, "sharesOutstanding": 96477569, "sharesShort": 9095903, "sharesShortPriorMonth": 8017399, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0943, "heldPercentInsiders": 0.031519998, "heldPercentInstitutions": 1.00636, "shortRatio": 2.77, "shortPercentOfFloat": 0.097600006, "impliedSharesOutstanding": 96477569, "bookValue": -0.83, "lastFiscalYearEnd": 1767139200, "nextFiscalYearEnd": 1798675200, "mostRecentQuarter": 1767139200, "netIncomeToCommon": -575000000, "trailingEps": -5.83, "forwardEps": -0.025, "enterpriseToRevenue": 4.116, "enterpriseToEbitda": -5.54, "52WeekChange": -0.52957356, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 22.72, "targetHighPrice": 120.0, "targetLowPrice": 25.0, "targetMeanPrice": 56.55, "targetMedianPrice": 50.5, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 20, "totalCash": 680000000, "totalCashPerShare": 7.052, "ebitda": -500000000, "totalDebt": 1252000000, "quickRatio": 2.188, "currentRatio": 2.477, "totalRevenue": 673000000, "revenuePerShare": 6.826, "returnOnAssets": -0.22035, "returnOnEquity": -6.08466, "grossProfits": -186000000, "freeCashflow": -251124992, "operatingCashflow": -466000000, "revenueGrowth": 0.259, "grossMargins": -0.27637, "ebitdaMargins": -0.74294, "operatingMargins": -0.54652, "financialCurrency": "USD", "symbol": "RARE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_117471985", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "regularMarketChangePercent": 4.07696, "regularMarketPrice": 22.72, "marketState": "CLOSED", "shortName": "Ultragenyx Pharmaceutical Inc.", "longName": "Ultragenyx Pharmaceutical Inc.", "fiftyTwoWeekHighChangePercent": -0.49511114, "fiftyTwoWeekChangePercent": -52.957355, "earningsTimestamp": 1770930000, "earningsTimestampStart": 1778014800, "earningsTimestampEnd": 1778014800, "earningsCallTimestampStart": 1770933600, "earningsCallTimestampEnd": 1770933600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -5.83, "epsForward": -0.025, "epsCurrentYear": -4.1505, "priceEpsCurrentYear": -5.4740396, "fiftyDayAverageChange": -4.779001, "fiftyDayAverageChangePercent": -0.17378817, "twoHundredDayAverageChange": -8.618801, "twoHundredDayAverageChangePercent": -0.27502012, "priceToBook": -27.373493, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1771633245, "regularMarketTime": 1771621201, "averageAnalystRating": "1.3 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391178600000, "postMarketChangePercent": -1.9366137, "postMarketPrice": 22.28, "postMarketChange": -0.43999863, "regularMarketChange": 0.889999, "regularMarketDayRange": "21.31 - 22.87", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2641038, "fiftyTwoWeekLowChange": 4.3099995, "fiftyTwoWeekLowChangePercent": 0.23411188, "fiftyTwoWeekRange": "18.41 - 45.0", "fiftyTwoWeekHighChange": -22.28, "market": "us_market", "esgPopulated": false, "displayName": "Ultragenyx Pharmaceutical", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]